Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:53:00.296Z.
Calculation as of: 2026-10-06T17:53:00.296Z.
Quote observation: 2026-10-06T17:50:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a212b8c45fb170636f79061a8993a9d466e21915543081357b5b59dac86f944c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$321.85M
EV/EBITDA Ratio
27.81x
TTM Avg
31.34x
3Y Avg
112.64x
5Y Avg
112.64x
Market Cap
$302.32M
EV/EBITDA Ratio
N/A
TTM Avg
22.81x
3Y Avg
22.81x
5Y Avg
22.81x
Market Cap
$302.90M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avita Medical Inc. (RCEL) | $319.65M | N/A | N/A | N/A | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $320.59M | N/A | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $318.98M | 8.33x | 20.16x | 20.16x | 12.62x |
| Sanara MedTech Inc. (SMTI)vs › | $321.85M | 27.81x | 31.34x | 112.64x | 112.64x |
| Cabaletta Bio, Inc. (CABA)vs › | $321.48M | N/A | N/A | N/A | N/A |
| CapsoVision, Inc. (CV)vs › | $324.92M | N/A | N/A | N/A | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $314.56M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $302.32M | N/A | 22.81x | 22.81x | 22.81x |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $302.90M | N/A | N/A | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $348.27M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute